Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:35:02 EST Sat 07 Feb 2026
Enter Symbol
or Name
USA
CA



Q:ATRA - ATARA BIOTHERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ATRA - Q0.24.72·5.480.14.88+0.378.2100.04328794.58  4.92  4.5819.145  4.2019:07:38Jan 1215 min RT 2¢

Recent Trades - Last 10 of 879
Time ETExPriceChangeVolume
19:07:38Q4.72820.21821
18:11:06Q4.780.271
16:30:59Q4.930.4220
16:10:04Q4.880.371
16:10:04Q4.880.371
16:04:43Q4.880.371
16:04:30Q4.880.371
16:04:21Q4.880.371
16:04:17Q4.880.371
16:00:32Q4.880.374

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-01-12 08:00U:ATRANews ReleaseAtara Biotherapeutics Provides Regulatory and Business Update on EBVALLO(TM) (tabelecleucel)
2025-11-12 09:00U:ATRANews ReleaseAtara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress
2025-11-03 09:00U:ATRANews ReleasePierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
2025-09-03 18:00U:ATRANews ReleaseAtara Biotherapeutics Announces Changes to Its Board of Directors
2025-08-11 16:01U:ATRANews ReleaseAtara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress
2025-07-24 08:57U:ATRANews ReleasePierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)
2025-07-24 08:00U:ATRANews ReleaseAtara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel(TM)) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease
2025-07-15 08:00U:ATRANews ReleasePerre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
2025-07-14 08:00U:ATRANews ReleaseAtara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel(TM))
2025-05-16 20:50U:ATRANews ReleaseAtara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors
2025-05-15 08:35U:ATRANews ReleaseAtara Biotherapeutics Announces First Quarter Financial Results and Operational Progress
2025-05-15 08:30U:ATRANews ReleaseAtara Biotherapeutics Announces Pricing of $16 Million Offering
2025-05-05 17:06U:ATRANews ReleaseAtara Biotherapeutics Provides Regulatory Updates on EBVALLO(TM) (tabelecleucel)
2025-03-07 16:01U:ATRANews ReleaseAtara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress